CRIS Current Research Information System

MURATORI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.519
AS - Asia 6.976
EU - Europa 5.260
AF - Africa 415
SA - Sud America 347
Continente sconosciuto - Info sul continente non disponibili 346
OC - Oceania 21
Totale 22.884
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.376
VN - Vietnam 2.177
CN - Cina 1.731
SG - Singapore 1.706
GB - Regno Unito 1.321
IT - Italia 918
DE - Germania 720
SE - Svezia 631
HK - Hong Kong 399
FR - Francia 325
IN - India 321
UA - Ucraina 305
RU - Federazione Russa 264
BR - Brasile 213
IE - Irlanda 169
JP - Giappone 126
NL - Olanda 115
BD - Bangladesh 113
FI - Finlandia 103
ZA - Sudafrica 102
KR - Corea 95
EE - Estonia 86
CI - Costa d'Avorio 83
SC - Seychelles 78
CA - Canada 74
TG - Togo 70
CH - Svizzera 66
AR - Argentina 63
PH - Filippine 52
BG - Bulgaria 34
TR - Turchia 34
AT - Austria 32
PL - Polonia 32
TH - Thailandia 31
BE - Belgio 30
JO - Giordania 30
MX - Messico 28
ID - Indonesia 27
IQ - Iraq 25
EC - Ecuador 22
GR - Grecia 21
NG - Nigeria 21
PK - Pakistan 20
TW - Taiwan 17
HR - Croazia 16
AU - Australia 14
ES - Italia 13
RO - Romania 13
EG - Egitto 12
MA - Marocco 12
IR - Iran 11
SA - Arabia Saudita 11
TN - Tunisia 11
JM - Giamaica 10
CO - Colombia 9
MY - Malesia 9
CL - Cile 8
KE - Kenya 8
LT - Lituania 8
PE - Perù 8
VE - Venezuela 8
PT - Portogallo 7
PY - Paraguay 7
UZ - Uzbekistan 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
NZ - Nuova Zelanda 6
DZ - Algeria 5
OM - Oman 5
AO - Angola 4
BO - Bolivia 4
GT - Guatemala 4
LB - Libano 4
NP - Nepal 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
AL - Albania 3
BY - Bielorussia 3
DK - Danimarca 3
NI - Nicaragua 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
IL - Israele 2
KZ - Kazakistan 2
LV - Lettonia 2
MK - Macedonia 2
PR - Porto Rico 2
PS - Palestinian Territory 2
AG - Antigua e Barbuda 1
AW - Aruba 1
BB - Barbados 1
BS - Bahamas 1
CG - Congo 1
CY - Cipro 1
Totale 22.515
Salva come PNG Salva come JPEG
Città #
Singapore 1.174
Southend 1.129
Ashburn 850
Fairfield 828
Chandler 595
Dong Ket 585
San Jose 476
Woodbridge 402
Houston 395
Santa Clara 394
Seattle 389
Ho Chi Minh City 381
Hong Kong 371
Wilmington 352
Hanoi 335
Cambridge 295
Princeton 253
Ann Arbor 247
Hefei 212
Beijing 203
Council Bluffs 202
Jacksonville 195
Boardman 174
Dublin 168
Bologna 149
Lauterbourg 117
Nanjing 116
Los Angeles 111
Tokyo 108
Padova 103
Westminster 101
Frankfurt am Main 96
Berlin 91
Milan 88
Helsinki 86
Jinan 85
Abidjan 83
New York 74
Buffalo 71
Lomé 70
Seoul 69
Da Nang 67
Dallas 67
Shenyang 60
Haiphong 58
Saint Petersburg 53
San Diego 53
Bern 52
Changsha 44
Rome 43
Des Moines 42
Phoenix 42
Hebei 40
Bremen 39
Mülheim 39
Guangzhou 37
Shanghai 36
Nanchang 35
Tianjin 34
Turin 34
Atlanta 32
Sofia 32
Amman 30
Redondo Beach 30
Brussels 28
Chicago 28
London 28
Zhengzhou 28
Munich 27
São Paulo 27
Hangzhou 25
Bengaluru 24
Medford 24
San Francisco 24
Haikou 21
Abeokuta 20
Chengdu 20
Mahé 20
Orem 20
Washington 20
Can Tho 19
Falls Church 19
Hải Dương 19
Jiaxing 19
Taiyuan 19
Vienna 19
Dearborn 18
Nuremberg 18
Toronto 18
Warsaw 18
Amsterdam 17
Bühl 17
Biên Hòa 16
Modena 16
Montreal 16
Taizhou 16
Fremont 15
Fuzhou 15
Moscow 15
Ningbo 15
Totale 13.950
Salva come PNG Salva come JPEG
Nome #
Easy recognition and high autoimmune hepatitis specificity of smooth muscle antibodies giving an actin microfilament immunofluorescent pattern on embryonal vascular smooth muscle cells 661
Development of autoimmune hepatitis after influenza vaccination; trigger or killer? 406
Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil antibodies in coeliac disease before and after gluten free diet. 308
COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? 283
A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis 280
Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. 279
Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver 276
Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. 259
Antinuclear antibodies in COVID 19 252
Clinical and serological profile of primary biliary cirrhosis in men. 250
Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. 243
'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? 242
Autoimmune liver disease and concomitant extrahepatic autoimmune disease 241
Anti-nuclear antibodies giving the “multiple nuclear dots” (MND) or the “rim-like/membranous” (RL/M) patterns: diagnostic accuracy for primary biliary cirrhosis. 238
Clinical features of type 1 autoimmune hepatitis in elderly Italian patients 237
Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C 233
Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. 229
A COMPLEX IMMUNOREGULATORY DEFICIENCY CHARACTERISES TYPE 1 AUTOIMMUNE HEPATITIS. 228
Autoimmune enteropathy and rheumatoid arthritis: A new association in the field of autoimmunity. 222
SPECIFICITY OF ANTI-SP100 ANTIBODY FOR PRIMARY BILIARY CIRRHOSIS. 220
Anti-actin IgA antibodies in severe coeliac disease 218
Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis. 213
Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy 210
Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases. 208
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 208
Antimitochondrial antibodies positive autoimmune hepatitis with acute onset 208
Acute icteric hepatitis induced by a short course of low-dose cyclophosphamide in a patient with lupus nephritis 207
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 206
Autoantibodies in Autoimmune Hepatitis 204
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 203
Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study 202
A case of leptospirosis simulating colon cancer with liver metastases 202
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 201
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 199
Virological analysis, genotypes and mutational patterns of the HBV pre-core/core gene in HBV/HCV-related hepatocellular carcinoma. 198
CLINICAL FEATURES OF PRIMARY BILIARY CIRRHOSIS IN YOUNG AND ELDERLY PATIENTS. 196
Blood-Based Non-Invasive Tests of Hepatic Fibrosis in Autoimmune Hepatitis: Application among Selected Patients Leads to Higher Accuracy 195
Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry 194
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 194
Diagnosis and therapy of autoimmune hepatitis. 193
Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. 190
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 190
Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype 188
Autoimmune liver disease 2007. 187
Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. 185
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 185
PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. 182
Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment 182
Autoimmune hepatitis in Italy: the Bologna experience. 181
Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study 181
Redistribution of regulatory T-cells across the evolving stages of chronic hepatitis C. 180
Antitransglutaminase antibodies and giardiasis 179
Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value 178
Anti-ribosomal P protein antibody: an autoreactivity devoid of prognostic value in patients with autoimmune hepatitis. 178
The western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis 177
Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. 177
Primary biliary cirrhosis specific anti-nuclear antibodies in patients from Spain. 176
Specific antinuclear reactivities in primary biliary cirrhosis 173
Clinical and serological profile of primary biliary cirrhosis in young and elderly patients. 172
Deamidated gliadin Peptide antibodies as a routine test for celiac disease: a prospective analysis. 171
PML NUCLEAR BODY COMPONENT SP140 IS A NOVEL AUTOANTIGEN IN PRIMARY BILIARY CIRRHOSIS. 171
Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. 170
Antifilamentous Actin Antibodies by ELISA for the Diagnosis of Type 1 Autoimmune Hepatitis. 170
Standardization of Autoantibody Testing in Autoimmune Hepatitis 169
Immunoglobulin GM and KM allotypes and prevalence of anti-LKM1 autoantibodies in patients with hepatitis C virus infection. 167
DETECTION OF MND AND RL/M ANTI-NUCLEAR ANTIBODIES PATTERNS: A RELIABLE DIAGNOSTIC TOOL IN ANTI-MITOCHONDRIAL ANTIBODIES NEGATIVE PRIMARY BILIARY CIRRHOSIS. 167
The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. 163
INCREASED REGULATORY POTENTIAL AND IMBALANCE OF THE VDELTA1/VDELTA2 RATIO IN PATIENTS WITH DIFFERENT MANIFESTATIONS OF HEPATITIS C. 163
Celiac disease in autoimmune cholestatic liver disorders 163
Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. 161
Diagnostic approach to autoimmune hepatitis 161
Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. 160
Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51 157
Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. 154
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 153
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. 152
Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis 151
Diagnosis of primary biliary cholangitis in a "teen" male patient 150
Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin 149
Le fonti energetiche rinnovabili nel contesto internazionale: il solare fotovoltaico ed i suoi sviluppi tecnologici 148
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. 148
Decompensated cirrhosis as presentation of LKM1/LC1 positive type 2 autoimmune hepatitis in adulthood. A rare clinical entity of difficult management 147
Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing 146
Coronavirus disease associated immune thrombocytopenia: Causation or correlation? 146
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 145
Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. 145
Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis 144
Autoantibodies in antimithocondrial antibodies negative primary biliary cholangitis. 143
Response to Efe et al. 142
Usefulness of Antibodies to Deamidated Gliadin Peptides in Celiac Disease Diagnosis and Follow-up. 142
Numerical investigation of blood flow in a stenotic artery. Target 1: geometry and rheology 141
Genetic distinction between autoimmune hepatitis in Italy and North America 141
Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting 141
Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C 140
Acute-on-chronic liver failure: A complex clinical entity in patients with autoimmune hepatitis 138
Serum Smooth Muscle Antibodies (SMA). 137
Autoantibodies to speckled protein family in primary biliary cholangitis 136
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 135
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis 135
Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset 127
Totale 19.276
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.552
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.552
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.244 0 49 169 220 201 124 50 168 100 177 567 419
2022/20232.442 326 342 128 314 139 186 87 135 388 95 189 113
2023/2024667 48 112 44 67 61 98 32 55 22 33 49 46
2024/20252.710 156 422 292 211 485 130 135 57 42 153 92 535
2025/20266.862 479 552 502 467 717 393 640 177 1.637 551 341 406
2026/20271.240 998 242 0 0 0 0 0 0 0 0 0 0
Totale 22.884